ketamine SC (BB106) / Bexson Biomedical - LARVOL DELTA

Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT (PRNewswire) - "Bexson Biomedical, Inc...announced the U.S. Patent and Trademark Office (USPTO) has issued patent 11,534,454 titled Complexing Agent Salt Formulations of Pharmaceutical Compounds....Bexson's formulation technology, branded as SEVALENT™, is the basis for the Company's lead therapy utilizing ketamine for post-operative pain management. This patent now expands the potential utility of its technology to a broad range of additional small molecules enabling intravenous (IV)-only therapies to be delivered subcutaneously in a controlled manner for use in the home setting."

Patent • Central Neuropathic Pain • CNS Disorders • Pain

Three Birds, One Excipient: Development of an Improved pH, Isotonic, and Buffered Ketamine Formulation for Subcutaneous Injection. (PubMed, Pharmaceutics) - "Subcutaneous (SC) ketamine has been found to be effective in pain management, though reports of injection site irritation and sterile abscesses exist with currently available ketamine HCl formulations. We describe the development of a novel Captisol-based formulation strategy to achieve an elevated pH, isosmotic and buffered formulation of ketamine (hence, three birds, one excipient) without compromising on concentration. This strategy has the potential to be readily adapted to other amine-based APIs."

Journal • Pain

Bexson Biomedical Announces Expansion to Treat Major Depression with Wearable Ketamine Formulation (PRNewswire) - "Bexson Biomedical, Inc...today announced it has received pre-IND guidance from the FDA for its lead ketamine compound for acute pain management. With this milestone reached, Bexson is expanding its ketamine development program to address mental health conditions such as Treatment Resistant Depression and Suicidality."

FDA event • Central Neuropathic Pain • CNS Disorders • Pain

Bexson Biomedical raises $4.8m in Series A round for subcutaneous ketamine treatment platform - "Bexson Biomedical has raised $4.8 million in a Series A financing round for developing a subcutaneous ketamine treatment platform for pain management and mental health disorders...company will use the funding for scaling up its pre-clinical and GMP manufacturing activities for its ketamine formulation, BB106..."

Financing • CNS Disorders • Pain